Wednesday, May 12, 2010

• Paradigm Medical Names Charles Pritchard as Vice President of Sales and Marketing --- SALT LAKE CITY, UT
  Posted at 7:30 AM
  SALT LAKE CITY, UT -- (Marketwire) -- 05/12/10 -- Paradigm Medical Industries, Inc. (PINKSHEETS: PDMI) announced today that Charles S. Pritchard has rejoined the Company as its Vice President of Sales and Marketing. Mr. Pritchard is a well known and respected sales manager in the ophthalmic community. He previously served as the National Sales Manager at Paradigm and, more recently, as National Sales Manager at Stereo Optics. Mr. Pritchard began work at Paradigm on May 11, 2010. "I am extremely ... read more
• ISTO Technologies, Inc. Announces Release of Peer-Reviewed Scientific Publication Related to Its Juvenile Cartilage Technology --- ST. LOUIS, MO
  Posted at 7:30 AM
  

  ST. LOUIS, MO -- (Marketwire) -- 05/12/10 -- ISTO Technologies, Inc. announced today the publication of a scientific paper in The American Journal of Sports Medicine (AJSM). The manuscript, titled "The Potential of Human Allogeneic Juvenile Chondrocytes for Restoration of Articular Cartilage" by H. Davis Adkisson et al., is currently available on-line at http://ajs.sagepub.com as an AJSM PreView article and will be included in the July 2010 edition of the leading peer-reviewed orthopaedic and sports medicine journal. The ... read more
• Recent Announcements Suggest Cellceutix Is Well Positioned With Autism Compound; Pfizer and Novartis Announcements Indicate Interest in Autism by Major Companies --- BEVERLY, MA
  Posted at 7:26 AM
  BEVERLY, MA -- (Marketwire) -- 05/12/10 -- Cellceutix Corporation (OTCBB: CTIX), a developer of small compounds for the treatment of cancer, autism and inflammatory diseases, believes that recent announcements by major pharmaceutical companies support its strategy of developing a novel compound to treat autism spectrum disorder. The New York Times published an article on April 29th to report the results from a small, overseas study for the treatment of fragile X syndrome by the Switzerland-based pharmaceutical giant Novartis. ... read more